Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS · Phase II

Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs 232

Quick answer

Neurology & CNS Phase II programs: NovaPharmaNews indexes 232 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 4 of 5

  1. PRENUMBRA

    Clinuvel Europe Limited

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  2. PTC518-CNS-002-HD

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  3. PTC857-CNS-001-ALS

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  4. PTT101

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  5. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  6. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  7. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  8. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  9. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  10. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  11. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  12. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  13. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  14. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  15. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial

  17. Placebo

    Teva Pharma GmbH

    Primary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  18. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  19. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  20. PrimeC

    NeuroSense Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  21. Proleukin

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  22. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  23. RAP-219

    Rapport Therapeutics

    Focal Epilepsy

    phase 2 small molecule active

    1 trial

  24. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  25. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  26. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial

  27. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  28. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  29. Risperidone

    Indivior Pty Ltd

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  30. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  31. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  32. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  33. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  34. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  35. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  36. SK-PC-B70M

    Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  37. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  38. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  39. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  40. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  41. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  42. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  43. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  44. Solriamfetol

    Axsome Therapeutics

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  45. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  46. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  47. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  48. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns Phase II programs exist?

232 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.